Seven Eight Capital, LP Genmab A/S Transaction History

Seven Eight Capital, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$34.88 - $43.22 $404,887 - $501,697	11,608 Added 79.99%	26,119 $986,000
Q4 2022 Feb 13, 2023	BUY	$33.8 - $47.06 $490,471 - $682,887	14,511 New	14,511 $614,000
Q2 2022 Aug 04, 2022	SELL	$26.83 - $38.57 $159,665 - $229,530	-5,951 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$30.95 - $39.68 $184,183 - $236,135	5,951 New	5,951 $215,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.